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ﬁ ndings. If a patient does well after surgery alone 
or with short-course radiotherapy and immediate 
surgery, we recommend discussion of the advantages 
and disadvantages of adjuvant chemotherapy. If 
the patient does not do well, the oncologist should 
not feel bad about not giving systemic therapy. If 
the patient had preoperative chemoradiotherapy, 
irrespective of response, we are as uncertain as other 
oncologists about what to recommend.
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Neoadjuvant chemotherapy is a well established 
approach to treatment of locally advanced breast 
cancer. Preoperative therapy allows breast-conserving 
surgery in many patients and provides prognostic 
information that could guide the choice of treatments 
to maximise the degree of response (ie, towards 
pathological complete remission [pCR]).1
At present, about 20% of patients achieve pCR after 
an appropriate neoadjuvant chemotherapy regimen, 
including a taxane and an anthracycline, and an anti-
HER2 drug for HER2-positive disease.2 Improved pCR 
is reported in subgroups of patients (eg, patients with 
triple-negative and HER2-positive disease) and in the 
presence of targeted therapies.3
The next step is to improve these results. The neo-
adjuvant setting is a suitable scenario in which 
new regimens can be tested rapidly with pCR as an 
endpoint. The strategy was highlighted recently by 
regulatory agencies that might grant accelerated 
approval of new drugs on the basis of an endpoint 
such as pCR, which is reasonably likely to predict 
survival beneﬁ t.4 
In the Neo-tAnGo study,5 Helena Earl and colleagues 
addressed the value of addition of gemcitabine to 
paclitaxel, and the sequencing of epirubicin and 
cyclophosphamide and paclitaxel (with or without 
gemcitabine) blocks. The investigators concluded 
that no advantage was provided in terms of pCR rate 
by addition of gemcitabine: 70 (17%) of 404 patients 
given epirubicin and cyclophosphamide then paclitaxel 
had pCR compared with 71 (17%) of 408 patients 
who received additional gemcitabine (p=0·98). 
Conversely, improved pCR was seen with taxane-
ﬁ rst sequencing for neoadjuvant chemotherapy: 
82 (20%) of 406 patients given paclitaxel with or 
without gemcitabine followed by epirubicin and 
cyclophosphamide achieved pCR compared with 
59 (15%) of 406 patients who received epirubicin and 
cyclophosphamide ﬁ rst (p=0·03).
The absence of a signiﬁ cant eﬀ ect for addition of 
gemcitabine is not surprising and is in line with results 
already reported in large phase 3 randomised studies 
in the neoadjuvant setting.6 These results however 
conﬁ rm the value of neoadjuvant trials for anticipation 
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of results of large adjuvant trials, which yielded much 
the same outcomes.7
The improved pCR reported in Neo-tAnGo5 with 
the taxane-ﬁ rst sequence did not translate into 
improved disease-free survival and overall survival. 
This ﬁ nding might be related to the small, albeit 
signiﬁ cant, diﬀ erence noted in the pCR (20% vs 15%). 
The overall low pCR (17%) was possibly related to the 
heterogeneous population, which included patients 
with inﬂ ammatory breast cancer.
Interpretation of eﬃ  cacy of neoadjuvant treatments 
might be improved by a selective focus on speciﬁ c 
subtypes of breast cancer. The Neo-tAnGo study,5 as 
is the case with most studies done in the neoadjuvant 
setting in the past few years, took no account of 
potential heterogeneity of tumour biology, which 
has been widely studied since such studies began.2 
The magnitude of the therapeutic eﬀ ect on pCR in 
patients with favourable and unfavourable prognosis 
might diﬀ er according to the intrinsic breast cancer 
subtype. von Minckwitz and colleagues3 explored, 
according to selected subtypes, the value of pCR in 
6377 patients with primary breast cancer who received 
neoadjuvant chemotherapy with an anthracycline and 
a taxane in seven randomised trials. They concluded 
that pCR is a good surrogate endpoint for patients 
with triple negative, luminal B (HER2-negative), and 
non-luminal (HER2-positive) disease, but not for 
patients with luminal A and luminal B/HER2-positive 
disease.
pCR according to subtypes should be taken into 
consideration when results of Earl and colleagues’ 
trial are interpreted. Although results were adjusted 
for HER2 and oestrogen receptor status, information 
on the taxane-ﬁ rst sequence was restricted in some 
subgroups (eg, HER2-positive disease). The regimen 
used in the study cannot be regarded as a present 
standard for patients with HER2-positive disease, 
because no targeted anti-HER2 agent was used. In 
the ACOSOG Z1041 trial,8 the value of a taxane-ﬁ rst 
sequence was not shown in patients with HER2-
positive disease in the neoadjuvant setting. pCR rates 
obtained in breast or nodes did not diﬀ er between two 
regimens in the analysis of anthracyclines followed 
by taxane plus trastuzumab compared with taxanes 
plus trastuzumab followed by anthracyclines plus 
trastuzumab.
Overall, a taxane-ﬁ rst sequence can be regarded as a 
reasonable option in neoadjuvant chemotherapy for 
locally advanced breast cancer. The results of Earl and 
colleagues’ study5 reinforce available evidence on the 
eﬃ  cacy of this sequence.9 In future trials, breast cancer 
should be regarded as a homogeneous disease until 
new evidence supports a diﬀ erent approach. However, 
we favour consideration of available information 
suggesting the biological heterogeneity of the disease. 
Therefore, investigations of tailored neoadjuvant 
treatments should aim at speciﬁ c groups of patients 
selected according to criteria of hypothetical 
responsiveness through international collaboration. 
This strategy will be key for progress to be made in the 
treatment of individual patients with locally advanced 
breast cancer.
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